EGFR is a highly expressed antigen in many cancers, including HNSCC, and its levels of expression have been shown to correlate with disease severity; therefore, cancer therapeutics targeting EGFR, such as cetuximab, have been developed and proved efficacious [28,29,30]. The gene discussed is EGFR; the disease is cancer.